Tag: BioSig

ViralClear Pharmaceuticals partners with Albany Molecular Research Inc. on the manufacture of merimepodib active pharmaceutical ingredient development for the potential treatment of COVID-19

Westport, CT, July 08, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it is partnering with Albany Molecular Research Inc., (AMRI), a leading global contract research, development and manufacturing organization (CDMO), for support in undertaking research to […]

BioSig Technologies Inc. Appoints Tony Zook to the Board of Directors

Former President and CEO of the North American division of AstraZeneca Plc to join as Independent Director Westport, CT, July 01, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity […]

BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering

Westport, CT, June 24, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 2,187,500 shares of the Company’s common stock, at a purchase price of $8.00 […]

BioSig Technologies Expands Intellectual Property Portfolio

Westport, CT, June 03, 2020 (GLOBE NEWSWIRE) — U.S. Patent and Trademark Office awards Company additional patent for PURE EP™ System Five patent applications filed by ViralClear Pharmaceuticals, Inc., covering its orally administered broad-spectrum anti-viral solution for the treatment of COVID-19 BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), […]

Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

Pharmaceutical industry leader to join as the Company prepares for the Phase II clinical trial with merimepodib, an orally administered broad-spectrum anti-viral for COVID-19 Westport, CT, May 28, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Michael R. Dougherty to the Board […]

Michael Schmertzler Joins the Board of ViralClear Pharmaceuticals, a Majority-Owned Subsidiary of BioSig Technologies, Inc.

Pharmaceutical expert and Chairman of PTC Therapeutics joins other biotech leaders as Independent Director Westport, CT, May 07, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Michael Schmertzler to the Board of Directors of its majority-owned subsidiary ViralClear Pharmaceuticals, Inc. Mr. Schmertzler […]

Tony Zook Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

Westport, CT, April 21, 2020 (GLOBE NEWSWIRE) — Former senior executive at AstraZeneca and pharmaceutical industry expert to join as Independent Director The Company is developing Vicromax(tm)  – a broad-spectrum orally administered anti-viral candidate for COVID-19 Upon receipt of FDA approval, Phase II clinical trial is planned to be conducted at […]

Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.

Former Chief Medical Officer of Celgene to lead development of Vicromax(tm), a novel broad-spectrum anti-viral agent that may treat COVID-19 Westport, CT, March 31, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced […]